Loading…
Godavari Drugs (BSE 530317)₹121.00−0.12%Pharmaceuticals
In the Mar 2026 quarter (standalone), Godavari Drugs reported sales of ₹33.22 Cr, up 30.1% from Mar 2025, and net profit of ₹1.28 Cr, up 45.5% year on year. For the year to Mar 2026, sales were ₹106 Cr and net profit ₹3.99 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 35.49 | 39.61 | 43.20 | 38.73 | 32.28 | 26.15 | 29.60 | 25.54 | 23.84 | 26.71 | 22.22 | 33.22 |
| Expenses | 33.19 | 36.48 | 39.60 | 34.20 | 29.01 | 23.22 | 27.01 | 22.41 | 20.94 | 24.68 | 19.73 | 30.26 |
| Operating Profit | 2.26 | 3.08 | 3.53 | 4.48 | 3.24 | 2.91 | 2.59 | 3.12 | 2.91 | 2.01 | 2.48 | 2.95 |
| OPM % | 6.4% | 7.8% | 8.2% | 11.6% | 10.1% | 11.2% | 8.7% | 12.2% | 12.2% | 7.5% | 11.2% | 8.9% |
| Other Income | 0.46 | 0.00 | 0.00 | 0.07 | 0.76 | 0.00 | 0.09 | 0.10 | 0.00 | 0.63 | 0.26 | 0.24 |
| Interest | 1.10 | 1.29 | 1.26 | 1.22 | 1.43 | 1.07 | 1.10 | 1.10 | 0.99 | 0.90 | 1.10 | 0.95 |
| Depreciation | 0.46 | 0.48 | 0.49 | 0.52 | 0.54 | 0.57 | 0.63 | 0.66 | 0.59 | 0.59 | 0.60 | 0.60 |
| Profit before tax | 1.13 | 1.29 | 1.75 | 2.80 | 2.02 | 1.26 | 0.94 | 1.45 | 1.32 | 1.14 | 1.03 | 1.63 |
| Tax % | 27.6% | 32.8% | 29.9% | 4.6% | 18.9% | 12.8% | 16.1% | 38.1% | 19.8% | 10.6% | 25.5% | 20.3% |
| Exceptional items | 0.00 | 0.00 | −0.05 | −0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.07 |
| Net Profit | 0.80 | 0.85 | 1.21 | 2.65 | 1.62 | 1.08 | 0.76 | 0.88 | 1.03 | 0.99 | 0.75 | 1.28 |
| EPS (Rs) | 1.07 | 1.13 | 1.63 | 3.54 | 2.15 | 1.46 | 1.01 | 1.17 | 1.37 | 1.34 | 1.02 | 1.26 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 71.11 | 76.16 | 64.15 | 84.19 | 96.20 | 123 | 161 | 160 | 157 | 113 | 106 | 106 |
| Expenses | 67.06 | 70.01 | 60.03 | 78.01 | 90.03 | 113 | 150 | 150 | 143 | 102 | 95.14 | 95.61 |
| Operating Profit | 4.01 | 5.01 | 4.01 | 5.01 | 6.01 | 10.02 | 11.02 | 10.02 | 13.01 | 12.01 | 10.01 | 10.35 |
| OPM % | 6.0% | 7.0% | 6.0% | 7.0% | 6.0% | 8.0% | 7.0% | 6.0% | 8.0% | 10.0% | 10.0% | 9.8% |
| Other Income | 0.00 | 1.01 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 0.99 | 1.13 |
| Interest | 1.99 | 2.99 | 1.99 | 2.99 | 2.99 | 2.99 | 2.99 | 3.99 | 4.99 | 4.98 | 3.99 | 3.94 |
| Depreciation | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 2.38 |
| Profit before tax | 2.01 | 3.01 | 1.01 | 2.01 | 2.01 | 6.02 | 7.02 | 5.02 | 7.02 | 6.02 | 5.01 | 5.12 |
| Tax % | 38.0% | 33.0% | 37.0% | 31.0% | 13.0% | 28.0% | 25.0% | 23.0% | 19.9% | 21.9% | 19.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | −0.06 | 0.04 | 0.28 | 0.27 |
| Net Profit | 0.99 | 1.99 | 0.99 | 0.99 | 1.99 | 3.99 | 4.99 | 3.99 | 5.99 | 3.99 | 3.99 | 4.05 |
| EPS (Rs) | 1.78 | 2.39 | 1.09 | 1.62 | 2.65 | 5.47 | 6.96 | 5.02 | 7.38 | 5.81 | 4.03 | 4.99 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.99 | 7.98 | 7.99 | 7.99 | 7.99 | 7.99 | 7.99 | 7.99 | 7.98 | 7.99 | 7.99 | 9.99 |
| Reserves | 6.01 | 7.02 | 9.02 | 10.02 | 11.02 | 13.03 | 17.03 | 22.05 | 26.07 | 31.04 | 36.01 | 66.10 |
| Borrowings | 8.02 | 16.04 | 16.03 | 19.04 | 22.04 | 28.06 | 30.07 | 23.05 | 36.06 | 58.08 | 64.07 | 76.08 |
| Other Liabilities | 12.97 | 20.93 | 23.97 | 26.97 | 32.89 | 35.88 | 35.88 | 48.93 | 51.89 | 37.82 | 34.83 | 47.76 |
| Total Liabilities | 34.99 | 50.97 | 56.01 | 63.02 | 73.94 | 83.96 | 90.97 | 101 | 121 | 135 | 143 | 200 |
| Fixed Assets | 7.01 | 9.01 | 13.02 | 15.02 | 15.02 | 14.01 | 22.04 | 26.03 | 25.02 | 27.04 | 33.02 | 30.01 |
| CWIP | 0.00 | 0.99 | 0.00 | 0.99 | 1.99 | 8.99 | 0.99 | 0.00 | 8.99 | 17.99 | 29.99 | 56.91 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 26.98 | 40.97 | 42.99 | 47.01 | 56.93 | 60.96 | 67.94 | 74.99 | 86.99 | 89.90 | 80.89 | 114 |
| Inventories | 9.27 | 10.75 | 11.33 | 13.48 | 16.48 | 17.77 | 14.66 | 10.04 | 19.87 | 20.64 | 27.93 | 46.04 |
| Trade receivables | 13.09 | 24.50 | 24.14 | 26.70 | 33.87 | 35.97 | 45.02 | 55.44 | 57.79 | 59.29 | 42.21 | 43.51 |
| Cash & equivalents | 0.25 | 0.64 | 0.87 | 1.61 | 1.52 | 1.42 | 1.63 | 2.27 | 3.07 | 2.61 | 2.36 | 14.50 |
| Total Assets | 34.99 | 50.97 | 56.01 | 63.02 | 73.94 | 83.96 | 90.97 | 101 | 121 | 135 | 143 | 200 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −6.01 | −5.02 | 5.01 | 4.01 | 4.01 | 6.02 | 1.01 | 11.04 | 13.03 | 18.06 | 11.03 | 1.01 |
| Cash from investing activity | 0.00 | −2.01 | −2.99 | −3.01 | −2.01 | −7.01 | −1.01 | −4.99 | −8.99 | −13.01 | −19.99 | −26.01 |
| Cash from financing activity | 5.98 | 6.98 | −1.99 | 0.00 | −0.99 | 0.00 | 0.00 | −5.98 | −3.99 | −5.98 | 7.98 | 36.86 |
| Net cash flow | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 0.00 | 0.00 | 12.01 |
| Capex | 0.19 | 2.07 | 3.76 | 3.61 | 2.57 | 6.87 | 1.66 | 5.24 | 9.29 | 13.17 | 19.97 | 26.69 |
| Free cash flow | −5.99 | −7.01 | 1.01 | 0.00 | 1.01 | −1.01 | 0.00 | 6.01 | 4.01 | 5.01 | −9.01 | −25.99 |
| CFO / OP % | −101.1% | −101.1% | 108.0% | 108.9% | 73.0% | 107.9% | 26.0% | 110.0% | 143.0% | 146.0% | 105.0% | 19.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 87 | 126 | 117 | 152 | 148 | 137 | 134 | 126 | 132 | 138 | 136 | 150 |
| Inventory days | 84 | 67 | 70 | 100 | 93 | 84 | 55 | 28 | 57 | 62 | 125 | 217 |
| Days payable | 79 | 108 | 124 | 171 | 171 | 144 | 112 | 121 | 132 | 96 | 128 | 163 |
| Cash conversion cycle | 91 | 84 | 62 | 80 | 69 | 77 | 77 | 32 | 57 | 104 | 132 | 203 |
| Working capital days | 64 | 45 | 41 | 48 | 39 | 32 | 47 | 33 | 24 | 10 | 12 | 43 |
| ROCE % | 32.1% | 16.0% | 17.1% | 11.1% | 12.1% | 12.1% | 18.1% | 18.1% | 14.1% | 14.1% | 10.1% | 7.0% |
For the Mar 2026 quarter, Godavari Drugs reported sales of ₹33.22 Cr, up 30.1% year on year and net profit of ₹1.28 Cr, up 45.5% year on year. The operating margin was 8.9%.
Godavari Drugs' sales for the year to Mar 2026 were ₹106 Cr; over the last twelve months they were ₹106 Cr.
Net profit for the year to Mar 2026 was ₹3.99 Cr, and ₹4.05 Cr over the last twelve months. Earnings per share over the same trailing period were ₹4.99.
Godavari Drugs reported borrowings of ₹76.08 Cr at Mar 2026, against cash and equivalents of ₹14.50 Cr.
Cash from operations was ₹1.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹25.99 Cr.